The Influence of Statin Therapy on Restenosis in Patients Who Underwent Nitinol Stent Implantation for de Novo Femoropopliteal Artery Disease: Two-Year Follow-up at a Single Center

Kim, Won-Ho; Gandhi, Ripal; Peña, Constantino; Herrera, Raul E.; Schernthaner, Melanie; Acuña, Juan; Becerra, Víctor; Katzen, Barry T.

doi:10.1016/j.jvir.2016.05.037

Cited by 14 publications

(6 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These findings are supported by RCT evidence from the Heart Protection Study; in a pre-specified subgroup analysis, treatment with simvastatin reduced the risk of a first major vascular event by 22% among patients with symptomatic PAD, compared with placebo [34]. Further beneficial effects of statin therapy have been observed in populations with atherosclerotic CVD including reducing the development or progression of claudication [35], and preventing restenosis following endovascular or open bypass revascularisation [36,37].…”

Section: Discussionmentioning

confidence: 89%

Morbidity and mortality associated with atherosclerotic peripheral artery disease: A systematic review

et al. 2020

View full text Add to dashboard Cite

PAD patients have a high risk of all-cause and cardiovascular (CV) mortality.• Patients with critical limb ischaemia were at highest risk (versus ABI < 0.9). • Fewer patients with critical limb ischaemia received statins (versus ABI < 0.9). • The risk of stroke or MI is at least equivalent to that of coronary artery disease.• Improved treatments are needed to attenuate CV risk in PAD patients.

show abstract

Section: Discussionmentioning

confidence: 89%

Morbidity and mortality associated with atherosclerotic peripheral artery disease: A systematic review

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Despite the fact that statins are associated with improved patency after surgical and endovascular procedures, the role of secondary prevention in limb salvage is a matter of debate. 13,24,25 A significant reduction of limb-specific events was observed in studies assessing patients with CLI and claudication; however, a number of CLI-specific studies failed to show a similar benefit in regard to major amputation rates. 9,10,21,22,[26][27][28] We assume that the high burden of peripheral atherosclerosis found in CLI may limit the impact of statins observed in the coronaries.…”

Section: Discussionmentioning

confidence: 99%

Association between statin therapy and amputation-free survival in patients with critical limb ischemia in the CRITISCH registry

Stavroulakis

Borowski

Torsello

et al. 2017

Journal of Vascular Surgery

View full text Add to dashboard Cite

show abstract

“…While the present study did not demonstrate a significant survival benefit with statins, patients taking statins had lower rates of significant restenosis requiring TLR in the stent group. A recent study showed that patients who underwent de novo treatment of femoropopliteal disease with nitinol stents had improved patency when taking statins compared to those who were not taking statins (30). …”

Section: Discussionmentioning

confidence: 99%

Treatment of Superficial Femoral Artery Restenosis

Miller

Takahashi

Harmsen

et al. 2017

Journal of Vascular and Interventional Radiology

View full text Add to dashboard Cite

Purpose To determine the predictors of restenosis, major adverse limb events (MALE), postoperative death (POD), and all-cause mortality after repeat endovascular treatment of superficial femoral artery (SFA) restenosis. Materials and Methods This is a retrospective review of 440 patients with 518 SFA lesions treated between January 2002 and October 2011. Ninety-six limbs were treated for restenosis with bare metal stents (BMS) or angioplasty (PTA) of which 28 limbs developed another restenosis requiring a third procedure. The interaction measured in this study was between the second and third intervention. Predictors of SFA patency, major adverse limb events (MALE), postoperative death (POD), and all-cause mortality after SFA restenosis treatment were identified. Results Patients treated with BMS (n = 51) had similar rates of restenosis compared to PTA (n = 45) (Hazard ratio [HR] 1.40; 95% confidence interval [CI] 0.68–2.90; P = 0.37). Patients in the BMS group taking statins had a significantly decreased risk of restenosis compared to patients not taking statins (HR 0.13; 95% CI 0.04–0.41; P < 0.001). Stage 4–5 chronic kidney disease (CKD) (n = 12) was associated with a significantly higher risk of MALE + POD (HR 6.17; 95% CI 1.45–26.18; P = 0.014) and all-cause mortality (HR 2.83; 95% CI 1.27–6.33; P = 0.01). Clopidogrel was protective against all-cause mortality (HR 0.41; 95% CI 0.20–0.80; P = 0.01). Conclusion Patients taking statins at the time of intervention in the BMS group had a significantly decreased risk of developing restenosis. Stage 4–5 CKD was a risk factor for MALE+POD and all-cause mortality while clopidogrel decreased all-cause mortality risk.

show abstract

The Influence of Statin Therapy on Restenosis in Patients Who Underwent Nitinol Stent Implantation for de Novo Femoropopliteal Artery Disease: Two-Year Follow-up at a Single Center

Cited by 14 publications

References 27 publications

Morbidity and mortality associated with atherosclerotic peripheral artery disease: A systematic review

Morbidity and mortality associated with atherosclerotic peripheral artery disease: A systematic review

Association between statin therapy and amputation-free survival in patients with critical limb ischemia in the CRITISCH registry

Treatment of Superficial Femoral Artery Restenosis

Contact Info

Product

Resources

About